Table 1.
All patients | |
---|---|
Age (mean, SD) | 11.2 (5.2) |
Female, N (%) | 24 (67) |
Race, N (%) | |
American Indian/Alaska Native | 1 (3) |
Black | 21 (58) |
Mixed | 1 (3) |
Unknown | 5 (14) |
White | 8 (22) |
Ethnicity, N (%) | |
Hispanic | 8 (22) |
Non-Hispanic | 27 (75) |
Unknown | 1 (3) |
ICU admission, N (%) | 25 (69) |
Intubated, N (%) | 18 (50) |
IV steroids, N (%)a | 35 (100) |
IVIG, N (%) | 35 (97) |
PLEX, N (%) | 23 (64) |
Second Line (Rituximab or cyclophosphamide), N (%) | 26 (72) |
Tumor present, N (%) | 5 (14) |
Prior ED visit or hospitalization before diagnosis, N (%) | 28 (78) |
Length of hospitalizationa Days, median (IQR) | 22 (12–40) |
MRI abnormal,a N (%) | 17 (49) |
EEG abnormal, N (%) | 31 (86) |
WBC Mean (SD) | 9.1 (3.6) |
NLR Median (IQR) | 2.3 (1.3, 3.9) |
LMR Mean (SD) | 4.8 (2.3) |
CSF WBC Median (IQR) | 11.0 (3.0, 38.0) |
Modified Rankin Scale at one year | 2.2 (1.2) |
SD: standard deviation, ICU: intensive care unit, IV: intravenous, IVIG: intravenous immunoglobulin, PLEX: plasmapheresis, ED: emergency department, LMR: lymphocyte to monocyte ratio; MRI: magnetic resonance imaging, EEG: electroencephalography, WBC: white blood cell, NLR: neutrophil to lymphocyte ratio, CSF: cerebrospinal fluid, IQR: interquartile range.
1 missing.